TCT-808 Comparison between Clopidogrel and the New Oral P2Y12 Inhibitors in the Treatment of Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention

Dual antiplatelet therapy improves angiographic results of primary percutaneous coronary intervention (pPCI) in patients with STEMI. The new oral P2Y12 inhibitors (P2Y12-I) prasugrel and ticagrelor are the gold-standard drugs because of a faster and more intense effect when compared to clopidogrel.